KẾT QUẢ BƯỚC ĐẦU CỦA HÓA XẠ TRỊ ĐỒNG THỜI VỚI PHÁC ĐỒ PACLITAXEL – CARBOPLATIN HÀNG TUẦN KẾT HỢP ĐỒNG THỜI VỚI XẠ TRỊ BỆNH UNG THƯ THỰC QUẢN TẠI BỆNH VIỆN CHỢ RẪY

Abstract

Background: This study was performed to assess the efficacy and feasibility of definitive chemoradiotherapy (dCRT) of weekly dose of combine Carboplatin/Paclitaxel (wCP) concurrent with radiation therapy for elderly patient with advanced esophageal carcinoma. Methods: Outcome of weekly Carboplatin-Paclitaxel based definitive chemoradiation in oesophageal cancer, in patients not considered suitable for Platinum-Fluoropyrimidine based treatment: a cross sectional review. Eligibility criteria included local, advanced, newly diagnosed; Eastern Cooperative Oncology Group (ECOG) score ≤ 2; and adequate organ function. Patient received concurrent chemoirradiation therapy consisting of radiotherapy (50Gy/25Fx to 60Gy/30Fx) and concurrent Paclitaxel (50mg/m2) and Carboplatin (area under the curve, AUC = 2) on day 1, 8, 15, 22 and 29. We assessed proportion of patients failure-free at response assessment (12 weeks post dCRT), treatment compliance and toxicity. Results: Between January, 2020, and Jun, 2022, 49 patients were treated. (55.10%) of patients were ≥60yrs; (22.44%) ≥65 yrs. Evaluation on chest CT by RECIST showed that response rate after treatment reached 38/49 (77.55%), of which complete response on chest CT and on endoscopy accounted for (42.85%), partial response accounted for (34.69%). There were 6 patient progressed (12.24%). Adverse events: mainly grade 1 toxicity, grade 2-3 toxicity during chemoradiationtherapy included neutropenia (8.16%), fatigue (4.08%), anaemia (2.04%), radiation dermatitis (2.04%), oesophagitis (4.08%) and vomiting (2.04%), no grade 4 toxicity and there were no treatment related deaths. Conclusions: In patients with locally advanced oesophageal cancer, the combination of weekly dose of Paclitaxel and Carboplatin was well tolerated and produced comparable results.